Prostate Cancer Staging (TNM): Understanding Your Cancer Stage
- What is cancer staging?
- TNM system – Tumor, Nodes, Metastasis
- T stage (Tumor) – T1 to T4
- N stage (Nodes) – N0 vs. N1
- M stage (Metastasis) – M0 vs. M1
- Stage grouping – Stage I, II, III, IV
- Risk groups – Low, intermediate, high, very high
- Prognosis by stage – survival rates
- Staging tests – MRI, CT, bone scan, PSMA PET
- Interactive FAQ – 9 questions about prostate cancer staging
What is cancer staging?
Cancer staging describes the extent of cancer in the body – how large the tumor is, whether it has spread to nearby lymph nodes, and whether it has metastasised (spread) to other organs. Staging determines prognosis and guides treatment decisions.
Prostate cancer staging uses the TNM system (Tumor, Nodes, Metastasis), which is combined with Gleason score and PSA to assign an overall stage (I-IV).
TNM system – Tumor, Nodes, Metastasis
The TNM system has three components:
- T (Tumor): How far has the primary tumor spread within and around the prostate?
- N (Nodes): Has cancer spread to nearby lymph nodes?
- M (Metastasis): Has cancer spread to distant organs (bones, lungs, liver)?
T stage (Tumor) – T1 to T4
T1 – Clinically inapparent (not palpable or visible on imaging):
- T1a: Incidental finding in <5% of resected tissue (e.g., from TURP for BPH)
- T1b: Incidental finding in >5% of resected tissue
- T1c: Found by needle biopsy (elevated PSA) – most common T1 stage
T2 – Tumor confined to the prostate:
- T2a: Involves one half of one lobe or less
- T2b: Involves more than one half of one lobe but not both lobes
- T2c: Involves both lobes
T3 – Tumor extends beyond the prostate capsule:
- T3a: Extracapsular extension (unilateral or bilateral)
- T3b: Tumor invades seminal vesicle(s)
T4 – Tumor invades adjacent structures:
- Bladder neck, external sphincter, rectum, levator muscles, or pelvic wall
N stage (Nodes) – N0 vs. N1
- N0: No regional lymph node metastasis
- N1: Metastasis in regional lymph node(s) (pelvic lymph nodes)
M stage (Metastasis) – M0 vs. M1
- M0: No distant metastasis
- M1: Distant metastasis present
M1 subcategories:
- M1a: Non-regional lymph nodes (outside the pelvis)
- M1b: Bone(s) – most common site of prostate cancer metastasis
- M1c: Other site(s) (lung, liver, brain) with or without bone metastasis
Stage grouping – Stage I, II, III, IV
Combining TNM with Gleason score and PSA gives the overall stage:
- Stage I: T1-T2, N0, M0, Gleason ≤6, PSA <10 – Localised, low risk
- Stage IIA: T1-T2, N0, M0, Gleason 3+4=7, PSA <20 – Localised, favorable intermediate
- Stage IIB: T1-T2, N0, M0, Gleason 4+3=7 or PSA ≥20 – Localised, unfavorable intermediate
- Stage IIC: T1-T2, N0, M0, Gleason 8 – Localised, high risk
- Stage IIIA: T3a or Gleason 9-10 (any PSA) – Locally advanced
- Stage IIIB: T3b-T4 – Locally advanced with seminal vesicle or adjacent organ invasion
- Stage IIIC: T3-T4 with Gleason 9-10 – High-risk locally advanced
- Stage IVA: N1 (any T, any PSA, any Gleason) – Regional lymph node metastasis
- Stage IVB: M1 (any T, any N, any PSA, any Gleason) – Distant metastasis
Risk groups – Low, intermediate, high, very high
Risk groups simplify treatment decisions:
Low risk:
- T1-T2a, Gleason ≤6, PSA <10
- Treatment: Active surveillance (preferred), surgery, or radiation
Intermediate risk (favorable):
- T2b-T2c, Gleason 3+4=7, PSA 10-20
- Treatment: Surgery, radiation, or active surveillance (select patients)
Intermediate risk (unfavorable):
- Gleason 4+3=7, or multiple intermediate risk factors
- Treatment: Surgery or radiation ± short-term hormone therapy
High risk:
- T3a, Gleason 8, PSA >20
- Treatment: Surgery or radiation + long-term hormone therapy (2-3 years)
Very high risk:
- T3b-T4, Gleason 9-10, or N1
- Treatment: Multimodal therapy (surgery + radiation or radiation + long-term hormone therapy)
Prognosis by stage – survival rates
| Stage | 5-Year Survival Rate | 10-Year Survival Rate |
|---|---|---|
| Localised (Stage I-II) | >99% | >98% |
| Locally Advanced (Stage III) | >95% | 85-90% |
| Regional Lymph Nodes (Stage IVA) | >90% | 70-80% |
| Distant Metastasis (Stage IVB) | 30-40% | 10-20% |
Staging tests – MRI, CT, bone scan, PSMA PET
Several tests are used to determine stage:
- Multiparametric MRI (mpMRI): Best for local staging (T stage) – shows extracapsular extension, seminal vesicle invasion
- PSMA PET/CT: Most accurate for lymph node (N) and distant metastasis (M) staging – now preferred over bone scan + CT
- Bone scan: Traditional test for bone metastases (being replaced by PSMA PET)
- CT abdomen/pelvis: For lymph node and visceral metastasis
When to perform staging imaging:
- Low risk: No imaging needed (risk of metastasis <1%)
- Intermediate risk: Consider PSMA PET or bone scan + CT
- High/very high risk: PSMA PET recommended
Interactive FAQ – Prostate cancer staging
T1-T2: cancer confined to prostate. T3: extends beyond capsule (T3a) or into seminal vesicles (T3b). T4: invades adjacent organs (bladder, rectum, pelvic wall).
Cancer has spread to regional lymph nodes (pelvic lymph nodes). This is Stage IVA and requires systemic therapy (hormone therapy).
Bones (spine, hips, ribs) – M1b. Bone metastases cause pain and can lead to fractures or spinal cord compression.
Stage IVB (distant metastasis) is not curable, but it is treatable. Hormone therapy can control the disease for years.
PSMA PET/CT is the most accurate for lymph node and metastasis staging. mpMRI is best for local staging (T stage).
For high-risk patients, PSMA PET is now preferred. Bone scan + CT is an alternative if PSMA PET is unavailable.
>99% at 5 years and >98% at 10 years. Most men with Stage I prostate cancer die from other causes, not prostate cancer.
Pathologic staging (pTNM) uses the surgical specimen – more accurate than clinical staging. pT2 = confined to prostate; pT3 = extracapsular extension.
Yes – many men with locally advanced (Stage III) prostate cancer can be cured with surgery (radical prostatectomy) or radiation + hormone therapy.
Disclaimer: This information is for educational purposes. Your cancer stage should be interpreted by a urologist in the context of your full clinical picture. Consult a specialist at Vivekananda Hospital.